哌拉西林/他唑巴坦优化给药方案的研究现状及临床合理应用

王钰莹, 王晓旋, 刘一, 冯婉玉

中国药学杂志 ›› 2016, Vol. 51 ›› Issue (18) : 1608-1614.

PDF(878 KB)
中国药学杂志
PDF(878 KB)
中国药学杂志 ›› 2016, Vol. 51 ›› Issue (18) : 1608-1614. DOI: 10.11669/cpj.2016.18.015
论著

哌拉西林/他唑巴坦优化给药方案的研究现状及临床合理应用

  • 王钰莹1, 王晓旋2, 刘一2*, 冯婉玉2
作者信息 +

Outcomes and Rational Clinical Use of Extended or Continuous Versus Intermittent Infusion of Piperacillin/Tazobactam

  • WANG Yu-ying1, WANG Xiao-xuan2, LIU Yi2*, FENG Wan-yu2
Author information +
文章历史 +

摘要

目的 概述哌拉西林他唑巴坦优化给药方案的研究进展,为临床合理应用提供参考。方法 检索国内外发表的相关文献,比较哌拉西林/他唑巴坦采用延长输注/持续输注优化给药方案与传统的间歇输注给药方案在生物药效学和临床试验中的差异。结果 优化后的给药方案能获得更高的药效学目标,临床疗效和细菌清除率至少不低于传统给药方案。结论 优化后的给药方案可以作为合理使用抗菌药物的优选给药方案应用于临床。

Abstract

OBJECTIVE To introduce the research progress of dosage regimen of piperacillin/tazobactam and its rational offer reference for clinical use.METHODS The domestic and oversea pertinent articles were searched, analyzed and summarized, and the difference between prolonged infusion or continuous infusion and traditional infusionin pharmacodynamics and clinical trials were compared. RESULTS The optimized dosage regimen could achieve higher pharmacodynamics goals, with clinical efficacy and bacterial clearance not inferior to the traditional dosage regimen.CONCLUSION The prolonged or continuous infusion strategy should be recommended for piperacillin/tazobactam in the clinic.

关键词

哌拉西林钠/他唑巴坦 / 延长输注/持续输注 / 优选给药方案 / 临床应用

Key words

piperzcillin/tazobactam / prolonged infusion/continuous infusion / alternative dosing regimen / clinical application

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
王钰莹, 王晓旋, 刘一, 冯婉玉. 哌拉西林/他唑巴坦优化给药方案的研究现状及临床合理应用[J]. 中国药学杂志, 2016, 51(18): 1608-1614 https://doi.org/10.11669/cpj.2016.18.015
WANG Yu-ying, WANG Xiao-xuan, LIU Yi, FENG Wan-yu. Outcomes and Rational Clinical Use of Extended or Continuous Versus Intermittent Infusion of Piperacillin/Tazobactam[J]. Chinese Pharmaceutical Journal, 2016, 51(18): 1608-1614 https://doi.org/10.11669/cpj.2016.18.015
中图分类号： R969.3   

参考文献

[1] HAWKEY P M,JONES A M. The changing epidemiology of resistance [J].Antimicrob Chemother,2009,64(1):3-10.
[2] JOSEPH S S,JOHN E M,JOHN S B,et al. Diagnosis and management of complicated intra-abdominal infection in adults and children:guidelines by the surgical infection society and the infectious diseases Society of America[J].Clin Infect Dis,2010,50(2):133-164.
[3] Diagnosis and management of community-and hospital-acquired pneumonia in adults[J/OL].NICE Clinical Guideline 191,2014,guidance. nice. org. uk/cg191.
[4] KIM A,SUTHERLAND C A,KUTI J L,et al. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections:prolonged or continuous infusion?[J].Pharmacotherapy,2007,27(11):1490-1497.
[5] BUCK C,BERTRAM N,ACKERMANN,et al. Pharmacokinetics of piperacillin-tazobactam:intermittentdosing vers us continuous infusion[J].Int J Antimicrob Agents,2005,25(1):62-67.
[6] GEORGES B,CONIL J M,COUGOT P,et al. Cefepime in critically illpatients:continuous infusion vs. an intermittent dosing regimen[J].Int J Clin Pharmacol Ther,2005,43(8):360-369.
[7] RAFATI M R,ROUINI M R,MOJTAHEDZADEH M,et al. Clinicalefficacyof continuous infusion of piperacillin compared with intermittentdosing in septic critically ill patients[J].Int J Antimicrob Agents,2006,28(2):122-127.
[8] AMOBROSE P G,BHAVNANI S M,RUBINO C M,et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy:it's not just for mice anymore[J].Clin Infect Dis,2007,44(1):79-86.
[9] LODISE T P,LOMAESTRO B M,DRUSANO G L. Application of antimicrobial pharmacodynamic concepts into clinical practice:focus on beta-lactam antibiotics:insights from the Society of Infectious Diseases Pharmacists[J].Pharmacotherapy,2006,26 (9):1320-1332.
[10] YE L Q,CAI T. Application of pharmacokinetics / pharmacodynamics model in optimization of antibiotic administration by Monte Carlo[J].Mod Pract Med(现代实用医学),2009,21(1):5-6.
[11] DERYKE C A,KUTI J L,NICOLAU D P. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa,Acinetobacter baumannii,Escherichia coli,and Klebsiella species collected from United States intensive care units in 2004[J].Pharmacotherapy,2007,27(3):333-342.
[12] ROBERTS J A,KIRKPATRICK C M,ROBERTS M S,et al. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis[J].Int J Antimicrob Agents,2010,35(2):156-163.
[13] CAI T,YE L Q. Pharmacodynamics of prolonged and continuous infusion regimens of three β-lactam antimicrobial agents against extended-spectrum β-lactamases producing bacteria[J].Chin J Nosocomiol(中华医院感染学杂志),2010,20(14):2110-2113.
[14] SHEA K M,CHEATHAM S C,WACK M F,et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin /tazobactam administered by prolonged infusion inhospitalized patients[J].Int J Antimicrob Agents,2009,34(5):429-433.
[15] LODISE T P,LOMAESTRO B,DRUSANO G L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection:clinical implications ofan extended-infusion dosing strategy[J].Clin Infect Dis,2007,44(3):357-363.
[16] GUILHERME H F,LEANDRO C,RODRIGO S M,et al. Pharmacokinetic/pharmacodynamic target attainmentof intravenous β-lactam regimens against Gram-negativebacteria isolated in a Brazilian teaching hospital[J].Rev Soc Bras Med Trop,2015,48(5):539-545.
[17] YE L Q,CAI T.Use of Monte Carlo simulation to optimize dosing regimens for Piperacillin-tazobactam [J].Chin J Clin Pharmacol Ther(中国临床药理学与治疗学),2010,15(8):901-905.
[18] HUI Y,ZHANG C H,ZHOU Q Y,et al. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam:a systematic review and Meta-analysis[J].PLoS One,2015,10(1):1-13.
[19] MATTHEW E F,GIANNOULA S T,KAZUROLKAWA,et al. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam:a systematic review and Meta-analysis[J].Clin Pract,2015,56(2):272-282.
[20] ZHANG X,ZHAI S D. Clinical outcomes with alternative dosing strategies for β-lactam antimicrobial:a Meta-analysis[C].Chinese Pharmacological Society,The Third Academic Annual Conference on therapeutic drug monitoring,Beijing,2015:22.
[21] ZHANG X M,HONG B,YE J H. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with respiratory tract infection[J].Chin J Clin Pharmacol Ther(中国临床药理学与治疗学),2015,20(6):677-681.
[22] HE C,SHEN L Y,DU Q S,et al. Clinical study on the treatment of Pseudomonas aeruginosa infection with piperacillin tazobactam according to PD/PK theoretical guidance[J].Mod Prev Med(临床合理用药),2014,7(10A):41-42.
[23] JOEL M D,JASON A,ROBERTS J S, et al. Continuous infusion of beta-lactam antibioticsin severe sepsis:a multicenter double-blind, randomized controlled trial[J].Clin Infect Dis,2013,56(2):236-244.
[24] LV Y, YAN Z,WANG D H,et al. Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperaeillin/tazobactam:prolonged vs regular infusion[J].Chin Crit Care Med(中华危重病急救医学),2013,25(8):479-483.
[25] LEE G C,LIOU H, YEE R,et al. Outcomes of extended-infusion piperacillin-tazobactam:a retrospective analysis of critically ill patients[J].Clin Ther,2012,34(12):2297-300.
[26] GONCALVES P J,OLIVEIRA B S, JANEIRO S,et al. Continuous infusion ofpiperacillin/tazobactam in septic critically ill patients-a multicenter propensity matched analysis[J].PLoS One,2012,7(11):e49845.
[27] YOST R J,CAPPELLRTTY D M, RECEIPT STUDY GRA, et al. The retrospective cohort of infusion piperacillin/tazobactam (RECEIPT) study:a multicenter study[J].Pharmacotherapy,2011,31(8):767-775.
[28] YE L Q, CAI T. Clinical study of extending administration time of piperacillin/tazobactam intreatment of Gram-negative bacteria infection [J].Chin J Nosocomiol(中国医院感染学杂志),2011,21(16):3476-3479.
[29] ROBERTS J A, KIRKPATRICK C M. Pharmacokinetics of piperacillin-tazobactam:intermittent dosing versus continuous infusion[J].Int J Antimicrob Agent,2005,25(1):62-67.
[30] LI Z Q,ZHANG Y G,WANG C Y,et al. Clinical efficacy of continuous infusion of piperacillin/tazobactam in severe pneumonia patients:a randomized controlled clinical trial[J].Mod Prev Med(现代预防医学),2010,37(15):2949-2951.
[31] LORENTE L, JIMENEZ A, MARTIN M M,et al. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion[J].Int J Antimicrob Agent,2009,33(5):464-468.
[32] PATEL G W, PATEL N,LAT A,et al. Outcomes of extended infusion piperacillin/tazobactam for documented gram-negative infections[J].Diagn Microbiol Infect Dis,2009,64(2):236-240.
[33] LODISE T P,LOMAESTRO B,DRUSANO G L. Piperacillin- tazobactam for Pseudomonas aeruginosa infection:clinical implications of an extended-infusion dosing strategy[J].Clin Infect Dis,2007,44(3):357-363.
[34] RAFATI M R,ROUINI M R,MOJTAHEDZADEH M,et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients[J].Int J Antimicrob　Agents,2006,28(2):122-127.
[35] LAU W K, MERCER D,ITANI K M,et al. Randomized,open-label,comparativestudy of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion fortreatment of hospitalized patients with complicated intra-abdominal infection[J].Antimicrob Agents Chemother,2006,50(11):3556-3561.
[36] BUCK C, BERTRAM N, ACKERMANN T,et al. Pharmacokinetics of piperacillin-tazobactam:intermittent dosingversus continuous infusion[J].Int J Antimicrob Agents,2005,25(20):62-67.
[37] GRANT E M,KUTI J L,NICOLAU D P,et al.Clinical efficacy andpharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital[J].Pharmacotherapy,2002,22(4):471-483.
[38] XAMPLAS R C,ITOKAZU G S,GLOWACKI R C,et al. Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital[J].Am J Health Syst Pharm,2010, 67(8):622-628.
[39] HEINRICH L S,TOKUMARU S,CLARK N M,et al. Development and implementation of a piperacillin-tazobactam extended infusion guideline [J].Pharm Pract,2011,24(6):571-576.
[40] FLOREA N R,KOTAPATI S,KUTI J L,et al. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam:a time-motion study[J].Am J Health Syst Pharm,2003,60(22):2321-2327.
[41] OBRINK-HANSEN K,JENSEN-FANGEL S,BROCK B,et al. Piperacillin/tazobactam continuous infusion at 12G/1.5G per day in CF patients results in targetplasma-concentrations[J].J Cyst Fibros,2016,16(2):e13-e14.
PDF(878 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉